Fludarabinphosphat-GRY® 25 mg/ml Konzentrat zur Herstellung einer Injektionslösung oder Infusionslösung clinical trials

Anti-CD 19 CAR-T cell therapy in patients with ANCA Vasculitis: A two-stage interventional, prospective, open-label, phase I/II trial in patients with active, treatment refractory, ANCA-IgG-positive vasculitis

This study is testing a new cell therapy called KYV-101 for a condition called ANCA vasculitis that hasn't responded to other treatments. It's looking at how safe the treatment is and if it can help reduce the antibodies that cause the condition.